MedTrace Logo

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan

NCT00417222 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1145

Last updated 2014-05-19

No results posted yet for this study

Summary

The purpose of this study is to investigate whether an angiotensin II receptor blocker (olmesartan), in addition to conventional treatment, will reduce the mortality and morbidity in hypertensive patients with stable chronic heart failure.

Conditions

Interventions

DRUG

olmesartan medoxomil

5 to 40mg P.O. daily until the end of the study

Sponsors & Collaborators

  • Tohoku University

    lead OTHER

Principal Investigators

  • Hiroaki Shimokawa, MD, PhD · Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2013-03-31
Completion
2013-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417222 on ClinicalTrials.gov